In 2022, the global onychomycosis treatment market is expected to be worth US$ 4.44 billion. From 2022 to 2032, the onychomycosis treatment market is expected to grow at an 8.46% CAGR and reach a value of US$ 10 billion. The market’s expansion can be attributed to the rising prevalence of diabetes, which increases the risk of nail fungus infection.
| Data Points | Key Statistics |
| Expected Market Value (2022) | US$ 4.44 Billion |
| Anticipated Forecast Value (2032) | US$ 10 Billion |
| Projected Growth Rate (2022-2032) | 8.46% |
Onychomycosis treatment has seen a high prevalence-low awareness scenario over the years, accounting for approximately 12% of the total fungal infection treatments space. However, the growing awareness of the potential threats posed by onychomycosis, as well as the increasing availability of treatments for the condition, point to a promising outlook for the onychomycosis treatment market in the coming years.
The roughly US$ 4.5 billion global market for onychomycosis treatment is expected to grow 6.4% year on year in 2019. In the near future, Future Market Insights’ new market research study sheds light on the increasing role of combination therapy recommendations in supporting demand growth for onychomycosis treatment.
Request Sample PDF Report@
https://www.futuremarketinsights.com/reports/sample/rep-gb-1279
Growing Inclination towards Combination Therapy to Boost Nail Lacquer Sales
Supporting recommendations for combination therapy by both podiatrists and dermatologists is cited as another significant factor driving global demand for onychomycosis treatment. According to research, combining systemic and topical therapies increases the cure rate, which is presumably encouraging onychomycosis patients to seek treatment that includes long-term antifungal medication, followed by the application of nail lacquers.
“Oral terbinafine has been a popular choice for including in the combination therapy over the years,” says a senior market research analyst at FMI, “which is followed by amorolfine nail lacquer in follow-up sessions.” The emergence of more such combination therapies as part of onychomycosis treatment is likely to support the market’s growth in the coming years.”
Nearly 80% Revenue Belongs to Distal Subungal Onychomychosis Treatment
Despite the fact that distal subungal onychomycosis is the most common disease indication driving treatment demand, accounting for nearly 80% of total market value, the report predicts that the prevalence of proximal subungal onychomycosis will rise significantly in the coming years.
North America & Western Europe Bag in over 70% Market Value Share
North American and Western European markets for onychomycosis treatment continue to provide the strongest push to market growth, accounting for more than 70% of total revenue. In addition to having the highest prevalence of onychomycosis, the North American landscape benefits greatly from the favourable reimbursement scenario in the US.
Ask to Analyst@
https://www.futuremarketinsights.com/ask-question/rep-gb-1279
Key Market Players considered in the Study:
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Medimetriks Pharmaceuticals, Inc.
- Galderma
- Johnson & Johnson
- Novartis AG
- Moberg Pharma AB
- Cardinal Health, Inc.
- Pfizer Inc.
- Almirall, S.A.
- Bayer AG
- Viatris Inc.
- GlaxoSmithKline plc
- Cipla Ltd.
- Dr. Reddy’s Laboratories Ltd
Analysis of the Moderately Consolidated Market Structure
Among the top performers in the global onychomycosis treatment landscape including Novartis AG, Galderma S.A., Valeant Pharmaceuticals, Inc., Johnson & Johnson Services, Pfizer, Inc., and others, the top five companies account for a global market share of over 43% – leaving the market as a moderately consolidated landscape. With an objective to achieve impactful product promotion campaigns, companies are signing sales and marketing agreements, according to the report.
- As indicated by recent research data, Valeant’s Jublia and Pfizer’s Diflucan have been the key brands responsible for sizable revenue generation in the onychomycosis treatment marketplace.
- Jublia continues to enjoy booming sales through the company’s D2C (direct-to-consumer) marketing strategy. Galderma’s Loceryl and Novartis’ Lamisil are also projected to retain higher attractiveness in the onychomycosis treatment landscape.
- The leading market players are likely to maintain their strategic focus on a strong sales channel and a versatile distribution network.
Buy this Report Now@
https://www.futuremarketinsights.com/checkout/1279
Onychomycosis Treatment Market Segmentation Analysis:
Treatment Type:
- Drugs
- Oral
- Rx
- OTC
- Topical
- Rx
- OTC
- Oral
- Lasers
- C02 Ablative Lasers
- Nd:YAG Lasers
- Dual-wavelength near-infrared Lasers
- Photodynamic Therapy
Disease Indication:
- Distal Subungual Onychomycosis
- White Superficial Onychomycosis
- Proximal Subungual Onychomycosis
- Candidal Onychomycosis
- Total Dystrophic Onychomycosis
Age Group:
- 0-18 Years
- 18-39 Years
- 40-64 Years
- 65 Years & Above
Gender:
- Male
- Female
Distribution Channel:
- Institutional Sales
- Hospitals
- Dermatology Clinics
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies & Online Sales
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (MEA)
Read Related Reports:
https://degentevakana.com/blogs/view/121254
https://vocal.media/stories/hypoparathyroidism-treatment-market-2022-scope-of-current-and-future-industry-2031
https://www.dronepilotlari.com/blogs/52528/Saudi-Arabia-Pharmaceutical-Market-2022-Key-Players-SWOT-Analysis-Key
https://vocal.media/stories/frontotemporal-disorders-treatment-market-2022-scope-of-current-and-future-industry-2028
About FMI
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
Report: https://www.futuremarketinsights.com/reports/onychomycosis-treatment-market
For Sales Enquiries: sales@futuremarketinsights.com
Browse latest Market Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs